Active substances: Orlistat
Erratum in: JAMA. JAMA Jan 8;289 Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society.
Glucose intolerance during diuretic therapy: results of trial by the European working party on hypertension in the elderly. Hepatic effects of dietary weight loss in morbidly obese subjects.
J Hepatol. Effects of liraglutide in the treatment of obesity: a randomised, double- blind, placebo-controlled study.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
Am J Cardiol. Pharmacological treatment of the overweight patient. Pharmacol Rev. Medical therapy for the patient with obesity.
Bariatric surgery: a systematic review and meta-analysis. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.
Am J Med. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development?
A systematic review of clinical studies.
Int J Clin Pract. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. N Engl J Med. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
I tend to see change as an engagement and active experience.